Recently, Altimmune announced data from the MOMENTUM phase 2 clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist in development for the treatment of obesity. Comprehensive analysis of patient body composition data showed that pemvidutide maintains patients' muscle mass while reducing weight, with 21.9% of weight loss attributed to muscle mass and 78.1% to fat.
减去体重中有近80%是脂肪！Altimmune公司新一代疗法积极结果公布
Remove the body weight with nearly 80% being fat! Altimmune's new generation therapy announces positive results.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.